Axsome Therapeutics AXSM Non Cash Lease Expense
Non Cash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept axsm:NonCashLeaseExpense.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's non cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's non cash lease expense?
- Axsome Therapeutics (AXSM) reported non cash lease expense of $844K in Q1 2026.
- How has Axsome Therapeutics's non cash lease expense changed year-over-year?
- Axsome Therapeutics's non cash lease expense increased by 38.6% year-over-year, from $609K to $844K.
- What is the long-term trend for Axsome Therapeutics's non cash lease expense?
- Over 3 years (2021 to 2025), Axsome Therapeutics's non cash lease expense has grown at a 41.3% compound annual growth rate (CAGR), from $1.08M to $3.05M.
- What does non cash lease expense mean?
- The non-cash portion of lease expenses recognized during the period.
- How do you interpret non cash lease expense?
- Stable levels indicate consistent lease obligations, while fluctuations may reflect changes in the lease portfolio.
- How does non cash lease expense compare across companies?
- Standard under IFRS 16 and ASC 842 lease accounting rules.